Skip to main content
Bavarian Nordic logo

Bavarian Nordic — Investor Relations & Filings

Ticker · BAVA ISIN · DK0015998017 LEI · 2138006JCDVYIN6INP51 CO Manufacturing
Open in API
Filings indexed 2,307 across all filing types
Latest filing 2023-06-20 Regulatory Filings
Country DK Denmark
Listing CO BAVA

About Bavarian Nordic

https://www.bavarian-nordic.com/

Bavarian Nordic is a fully integrated biotechnology company specializing in the research, development, manufacturing, and commercialization of life-saving vaccines. The company's portfolio targets infectious diseases, including vaccines for Mpox, rabies, and typhoid. It is a leading global provider of travel vaccines and serves as a key partner for governments and international organizations in addressing public health preparedness needs.

Recent filings

Filing Released Lang Actions
Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Bavarian Nordic regarding clinical trial results for a vaccine candidate. It does not fit into financial reporting categories like 10-K, IR, or ER, nor does it relate to corporate governance, M&A, or share transactions. As it is a general regulatory announcement regarding company operations and clinical progress that does not fall into the other specific categories, it is classified as a Regulatory Filing (RNS).
2023-06-20 English
Regulatory Filings 2023
Regulatory Filings Classification · 99% confidence The document is titled "Selskabsmeddelelse" (Company Announcement) and reports specific clinical trial results (Phase 2 data for a COVID-19 booster candidate, ABNCoV2) and provides an update on the ongoing Phase 3 trial timeline. It includes forward-looking statements and contact information typical of a press release announcing material, non-financial operational news. This format strongly suggests an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (like 10-K or IR) but an announcement of specific operational/clinical data, and it is not explicitly a proxy statement (DEF 14A) or a management discussion (MDA), the most appropriate classification for a material, non-financial announcement that isn't a standard financial report is Earnings Release (ER), as these often include operational highlights, or Regulatory Filing (RNS) as a fallback. Given the content is a specific, time-sensitive announcement of trial results, ER is often used for such operational updates, even if not strictly quarterly earnings. However, since it is a specific clinical update rather than a summary of financial performance, RNS (Regulatory Filings/General Announcement) is a safer fit for non-standard operational news, or ER if we interpret 'results' broadly. Given the structure and the fact it's a formal announcement of key data points, I will classify it as an Earnings Release (ER) as these often encompass key operational milestones alongside financial figures, or RNS if it's purely operational. Since it focuses heavily on clinical data and outlook, and is not a standard financial report, RNS is the best fit for a general regulatory announcement that doesn't fit the other specific categories, although ER is plausible if the company groups clinical updates here. I will lean towards RNS as the most general fit for a non-financial, material announcement.
2023-06-16 Danish
Regulatory Filings 2023
Regulatory Filings Classification · 99% confidence The document is a press release titled "Bavarian Nordic Reports 12-Month Durability Data from a Phase 2 Clinical Trial of its COVID-19 Vaccine Candidate." It details clinical trial results, provides management commentary, and includes forward-looking statements. This structure is typical of an Earnings Release (ER) or a general corporate announcement. Since it is reporting specific, periodic results (clinical trial data update) rather than a full financial statement (10-K or IR), and it is an announcement of results, ER is the most appropriate fit among the options. It is not a transcript (CT), a formal annual report (10-K), or a pure governance/remuneration document. The presence of an 'Attachment' link and the relatively short length (under 5,000 characters) suggests it might be an announcement *of* a report, but the content itself is the core news release of the results, making ER stronger than RPA, unless the results were only summarized in the attachment. Given the content is the primary news, ER is selected.
2023-06-16 English
Bavarian Nordic Reports 12-Month Durability Data from a Phase 2 Clinical Trial of its COVID-19 Vaccine Candidate
Regulatory Filings Classification · 98% confidence The document is a press release from Bavarian Nordic announcing clinical trial results for their COVID-19 vaccine candidate. It provides a summary of findings from a phase 2 study. While it contains scientific data, it is a corporate announcement rather than a full audit report, financial statement, or regulatory filing. It fits the definition of a general regulatory announcement (RNS) as it is a company announcement (Selskabsmeddelelse nr. 24 / 2023) regarding operational/clinical progress.
2023-06-16 Danish
Bavarian Nordic Reports 12-Month Durability Data from a Phase 2 Clinical Trial of its COVID-19 Vaccine Candidate
Regulatory Filings Classification · 98% confidence The document is a company announcement regarding clinical trial results for a vaccine candidate. It does not fit into financial reporting categories like 10-K, IR, or ER, nor does it represent a corporate governance or shareholder event. As it is a general regulatory announcement regarding company operations and R&D progress that does not fall into the other specific categories, it is classified as a Regulatory Filing (RNS).
2023-06-16 English
Director's Dealing 2023
Director's Dealing Classification · 100% confidence The document text is titled 'Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier' (Reporting of transactions in Bavarian Nordic shares by senior employees and their close relations). It details specific share transactions (Køb/Buy) made by board members (Anders Gersel Pedersen, Peter Kürstein, Frank Verwiel, Anne Louise Eberhard) on June 12, 2023. This content directly corresponds to the definition of reporting personal share transactions by company directors and executives, which maps to the 'Director's Dealing' category. This is a specific regulatory disclosure, not a general announcement of a report (RPA/RNS), nor is it a full annual report (10-K) or an earnings release (ER). Therefore, the appropriate code is DIRS.
2023-06-12 Danish

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.